SixPeaks Bio

轩竹医药是一家新分子实体创新药物研发商，主要进行新分子实体药物的研究和开发，研究的领域主要包括抗感染领域、抗心血管代谢疾病领域、抗肿瘤领域等比较前沿的新药研发领域。公司在创新药领域的投资已超20亿，目前已经形成完整的新药研究开发体系，具有从新药结构设计、评价、确立候选化合物，到临床研究，再到新药上市申请的专业平台。

Spyre Therapeutics was acquired by Aeglea BioTherapeutics.Spyre Therapeutics was a biotechnology company focused on developing antibody therapeutics for the potential treatment of inflammatory bowel disease (IBD).The company had been founded as a spin-out of Paragon Therapeutics, its second spin-out company.In June 2023, the company was acquired by Aeglea BioTherapeutics. The transaction was structured as as a stock-for-stock transaction whereby all of Spyre's outstanding equity interests were exchanged based on a fixed exchange ratio, combining 13,013,636 shares of Aeglea common stock and 364,889 shares of Series A preferred stock (or 364,889,000 shares) on an as-converted-to-common basis

轩竹医药是一家新分子实体创新药物研发商，主要进行新分子实体药物的研究和开发，研究的领域主要包括抗感染领域、抗心血管代谢疾病领域、抗肿瘤领域等比较前沿的新药研发领域。公司在创新药领域的投资已超20亿，目前已经形成完整的新药研究开发体系，具有从新药结构设计、评价、确立候选化合物，到临床研究，再到新药上市申请的专业平台。